Loading market movers...

Lenvatinib

Phase 3

00%

Phase 3

Development Phase

4

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q1 '27

MRKPhase 2$364.4B

Lenvatinib Phase 2 Est. Readout

Lenvatinib• Non-small Cell Lung Cancer730

Q1 2027~QConfirmed

00%

Dec '26

MRKPhase 2$364.4B

Lenvatinib Phase 2 Est. Readout

Lenvatinib• Non-small Cell Lung Cancer40

Dec 2026~Confirmed

00%

Oct '26

MRKPhase 2$364.4B

Lenvatinib Phase 2 Est. Readout

Lenvatinib• Non-small Cell Lung Cancer30

Oct 2026~Confirmed

00%

Oct '26

MRKPhase 3$364.4B

Lenvatinib Phase 3 Est. Readout

Lenvatinib• Non-small Cell Lung Cancer1,653

Oct 2026~Confirmed

00%

Competitive Landscape

12 competitors in Non-small Cell Lung Cancer

SNYoxaliplatine / gemcitabine / Vinorelbine

RHHBYerlotinib HCl

View Full Landscape

Drug Information

Target Indication

Non-small Cell Lung Cancer

Clinical Trial

Last updated: 12/16/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Diabetic Retinopathy

alendronate with cholecalciferolPhase 3

Osteoporosis

Simvastatin 20 mg dailyPhase 3

Cardiovascular Disease

EpinephrinePhase 3

Malignant Neoplasms of Male Genital Organs

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3

HPV Positive Oropharyngeal Squamous Cell Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts